Zinc finger protein 384 (ZNF384) impact on childhood mixed phenotype acute leukemia and B-cell precursor acute lymphoblastic leukemia

dc.contributor.authorSudutan, Tugce
dc.contributor.authorErbilgin, Yucel
dc.contributor.authorHatirnaz Ng, Ozden
dc.contributor.authorKaraman, Serap
dc.contributor.authorKarakas, Zeynep
dc.contributor.authorKucukcankurt, Fulya
dc.contributor.authorCelkan, Tiraje
dc.contributor.authorTimur, Cetin
dc.contributor.authorOzdemir, Gul Nihal
dc.contributor.authorHacisalihoglu, Sadan
dc.contributor.authorGelen, Sema Aylan
dc.contributor.authorSayitoglu, Muge
dc.date.accessioned2023-02-21T12:39:28Z
dc.date.available2023-02-21T12:39:28Z
dc.date.issued2022-01-01
dc.description.abstractB-cell precursor acute lymphoblastic leukemia (BCP-ALL) is a heterogeneous malignancy and consists of several genetic abnormalities. Some of these abnormalities are used in clinics for risk calculation and treatment decisions. Patients with ZNF384 rearrangements had a distinct expression profile regardless of their diagnosis, BCP-ALL or mixed phenotype acute leukemia (MPAL) and defined as a new subtype of ALL. In this study, we screened 42 MPAL and 91 BCP-ALL patients for the most common ZNF384 fusions
dc.description.abstractZNF384::TCF3, ZNF384::EP300 and ZNF384::TAF15 by using PCR. We identified ZNF384 fusions in 9.5\% of MPAL and 7.6\% of BCP-ALL. A novel breakpoint was identified in ZNF384::TCF3 fusion in one BCP-ALL patient. T-myeloid MPAL patients showed significantly lower ZNF384 expression compared to lymphoid groups. Patients with ZNF384r had intermediate survival rates based on other subtypes. Prognostic and patient-specific treatment evaluation of ZNF384 fusions in both ALL and MPAL might help to improve risk characterization of patients.
dc.description.issue12
dc.description.issueOCT 15
dc.description.pages2931-2939
dc.description.volume63
dc.identifier.doi10.1080/10428194.2022.2095630
dc.identifier.urihttps://hdl.handle.net/11443/2511
dc.identifier.urihttp://dx.doi.org/10.1080/10428194.2022.2095630
dc.identifier.wosWOS:000835775800001
dc.publisherTAYLOR \& FRANCIS LTD
dc.relation.ispartofLEUKEMIA \& LYMPHOMA
dc.subjectB-cell precursor ALL
dc.subjectmixed phenotype acute leukemia
dc.subjectZNF384 fusion
dc.subjectZNF384 expression levels
dc.titleZinc finger protein 384 (ZNF384) impact on childhood mixed phenotype acute leukemia and B-cell precursor acute lymphoblastic leukemia
dc.typeArticle

Files

Collections